Anti-Interleukin-1 Agents in Adult Onset Still's Disease

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left"> Biologic agent target cytokine(s)</td><td align="left">Molecular characteristics</td><td align="left">Doses (route of administration)</td><td align="left">Recorded indications</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">Anakinra (Kineret) IL-1<i>α</i> and IL-1<i>β</i></td><td align="left">Recombinant human IL-1 receptor antagonist</td><td align="left">100 mg/day (sc)</td><td align="left">Rheumatoid arthritis</td></tr><tr><td align="left">Rilonacept (Regeneron) IL-1<i>α</i> and IL-1<i>β</i></td><td align="left">Fusion protein of the extracellular domains of IL-1R1 and IL-1RAP, coupled to the Fc region of human IgG</td><td align="left">Induction dose: 320 mg maintenance: 160 mg/week (sc)</td><td align="left">Cryopyrin-associated periodic syndromes (CAPSs)</td></tr><tr><td align="left">Canakinumab (Ilaris) IL-1<i>β</i></td><td align="left">Fully human monoclonal anti-IL1<i>β</i> antibody</td><td align="left">150 mg every 8 weeks (sc)</td><td align="left">Cryopirin-associated periodic syndromes (CAPSs)</td></tr><tr><td align="left">Gevokizumab (Xoma 052) IL-1<i>β</i></td><td align="left">Recombinant humanized anti-IL1<i>β</i> antibody</td><td align="left"></td><td align="left">Not labeled potential therapeutic use: Behçet's uveitis, types 1 and 2 diabetes, and rheumatoid arthritis (phase II trials)</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>sc: subcutaneous.<br/></td></tr></table>

International Journal of Inflammation

tab1

Table 1

Table 1: Anti-Interleukin-1 Agents in Adult Onset Still's Disease 